{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"97.5","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"97.5","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"52.2","value":"0.0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"70.8","value":"0.0"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"97.5","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"description":"ORR was assessed by the investigator per 2017 ELN Response Criteria for AML and was defined as the combined percentage of participants with CR, CRi, and partial remission (PR). CR was defined as bone marrow blasts \\<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC ≥1.0 × 10\\^9/L (1000/µL); platelet count ≥100 × 10\\^9/L (100,000/µL)\\]. CRi was defined as all CR criteria except for residual neutropenia (\\<1.0 × 10\\^9/L \\[1000/µL\\]) or thrombocytopenia (\\<100 × 10\\^9/L \\[100,000/µL\\]). PR was defined as all hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pre-treatment bone marrow blast percentage by at least 50%). ORR was reported for each arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were to receive 7.5 mg of MK-0482 via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks \\[Q3W\\]) for up to 35 cycles (approximately 24 months).","id":"OG000","title":"MK-0482 7.5 mg Q3W"},{"description":"Participants were to receive 25 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG001","title":"MK-0482 25 mg Q3W"},{"description":"Participants were to receive 75 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG002","title":"MK-0482 75 mg Q3W"},{"description":"Participants were to receive 225 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG003","title":"MK-0482 225 mg Q3W"},{"description":"Participants were to receive 750 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG004","title":"MK-0482 750 mg Q3W"}],"paramType":"NUMBER","populationDescription":"All allocated participants who received at least 1 dose of study intervention and had a baseline assessment were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to approximately 10 months","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}